Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2 Billion
October 10, 2025
Akero Therapeutics announced it has entered into a definitive agreement to be acquired by Novo Nordisk A/S in a transaction valued at up to $5.2 billion in cash. Under the terms of the deal, Akero shareholders will receive $54.00 per share at closing plus a non-transferable Contingent Value Right (CVR) that could pay an additional $6.00 per share contingent on full U.S. regulatory approval of efruxifermin (EFX) for compensated cirrhosis associated with MASH.
- Buyers
- Novo Nordisk A/S
- Targets
- Akero Therapeutics
- Industry
- Pharmaceuticals
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Merck to Acquire Acceleron Pharma Inc for $11.5B
September 30, 2021
Biotechnology
Merck (through a subsidiary) entered into a definitive agreement to acquire Acceleron Pharma Inc for $180 per share in cash, for an approximate total equity value of $11.5 billion. The transaction will be completed via a tender offer followed by a merger, and is expected to close in the fourth quarter of 2021, subject to conditions including regulatory approvals and tender of at least a majority of outstanding shares.
-
Novo Nordisk to Acquire Cardior Pharmaceuticals for Up to €1.025 Billion
March 25, 2024
Biotechnology
Novo Nordisk agreed to acquire Cardior Pharmaceuticals for up to €1.025 billion, consisting of an upfront payment plus additional milestone payments tied to development and commercial progress. The deal is expected to strengthen Novo Nordisk’s cardiovascular pipeline, centered on Cardior’s lead candidate CDR132L in phase 2 heart failure trials.
-
Novo Nordisk Acquires Forma Therapeutics
September 1, 2022
Pharmaceuticals
Novo Nordisk will acquire Forma Therapeutics in a cash tender offer at $20 per share, valuing the deal at about $1.1 billion. The acquisition is intended to expand Novo Nordisk’s scientific and pipeline presence in sickle cell disease and other rare blood disorders, including Forma’s lead candidate etavopivat.
-
Danaher Acquires Aldevron for $9.6 Billion
June 17, 2021
Biotechnology
Danaher Corporation entered into a definitive agreement to acquire Aldevron from EQT Private Equity for an enterprise value of approximately USD 9.6 billion. Aldevron, headquartered in Fargo, North Dakota with ~600 employees and additional operations in Madison, Wisconsin, will operate as a standalone company within Danaher's Life Sciences segment to expand Danaher's capabilities in genomic medicine and biologics manufacturing.
-
Pharmacosmos A/S Acquires AbFero Pharmaceuticals, Inc.
November 11, 2021
Pharmaceuticals
Pharmacosmos A/S (Pharmacosmos Group) has agreed to acquire all assets of Boston-based clinical-stage AbFero Pharmaceuticals, Inc. under a share purchase agreement for up to $225 million including upfront, milestone, and royalty components. The acquisition adds AbFero’s SP-420 iron chelation program to Pharmacosmos’ iron-metabolism-focused R&D and commercial capabilities to accelerate development and commercialization for transfusional iron overload and related indications.
-
Astellas Acquires IVERIC bio for Approximately $5.9 Billion
April 29, 2023
Biotechnology
Astellas Pharma has agreed to acquire 100% of IVERIC bio for $40.00 per share, implying an aggregate equity value of roughly $5.9 billion. The acquisition strengthens Astellas' ophthalmology capabilities and adds Iveric's lead program avacincaptad pegol (ACP) for geographic atrophy secondary to AMD to Astellas' pipeline.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.